Medicine and food for preventing or treating COVID-19 and application thereof

A COVID-19 and drug technology, applied in the field of medicine, can solve the problems of toxicity, poor effect of viral pneumonia, and no obvious activity of COVID-19

Active Publication Date: 2020-12-25
GUANGZHOU CENTURY CLINICAL RES CO LTD +4
View PDF7 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, broad-spectrum antiviral drugs have no obvious activity against COVID-19, and many drugs for symptomatic treatme

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine and food for preventing or treating COVID-19 and application thereof
  • Medicine and food for preventing or treating COVID-19 and application thereof
  • Medicine and food for preventing or treating COVID-19 and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0087] Example 1: Application of lysozyme in patients with new coronary pneumonia and high-risk infection groups

[0088] During the COVID-19 epidemic, our company donated more than 2 million yuan of medicines to Hubei Province twice, including antibacterial drugs such as lysozyme buccal tablets and lysozyme enteric-coated tablets. We found that these drugs played a positive role in the fight against the new crown epidemic.

[0089] There were 9 newly diagnosed patients with new coronary pneumonia who took the lysozyme buccal tablets and / or lysozyme enteric-coated tablets provided by us. The dosage ranged from 0.5g to 2g per day. severe, and the other 8 were all mild and recovered later. The calculated severe conversion rate was 11.1%.

[0090] There are 3 people who lived and traveled in high-risk areas during the epidemic. They insisted on taking lysozyme buccal tablets and / or lysozyme enteric-coated tablets every day. Coronavirus, 0% infection rate.

[0091] According t...

Embodiment 2

[0092] Example 2: In vitro test of lysozyme against new coronavirus

[0093] The anti-COVID-19 novel coronavirus effect of lysozyme was studied with African green monkey kidney cells.

[0094] Drugs: lysozyme, monoammonium glycyrrhizinate.

[0095] Cells: Vero cells (VeroE6 cells).

[0096] Virus: COVID-19, a titer of 100TCID was used 50 .

[0097] Culture: sterile 96-well culture plate, add 100 μL to each well with a concentration of 2×10 5Cells / mL VeroE6 cells were cultured at 37°C for 24 hours. The culture plates were divided into blank control group, virus control group, low-dose lysozyme group, middle-dose lysozyme group, high-dose lysozyme group, low-dose monoammonium glycyrrhizinate group, and high-dose monoammonium glycyrrhizinate group. 3 holes. In addition to the blank control group, 100TCID was added to each group 50 Virus solution 100 μL / well, 5% CO at 37°C 2 After 2 hours of adsorption in the incubator, discard the cell culture medium in the culture plate....

Embodiment 3

[0103] Example 3: In vitro test of combination containing lysozyme against new coronavirus and inflammation caused by new coronavirus

[0104] To study the inhibitory effect of the combination containing lysozyme on the cytopathy caused by the COVID-19 virus, and the inhibitory effect on the inflammation caused by the COVID-19 virus.

[0105] Medicine, cell, virus etc. are all identical with embodiment 2.

[0106] The grouping and dosage of the culture plate are: blank control group, virus control group, lysozyme group (350 μg / ml), lysozyme monoammonium glycyrrhizinate I group (100 μg / ml+1 μg / ml), lysozyme monoammonium glycyrrhizinate Group II (100 μg / ml+5 μg / ml), group III of lysozyme monoammonium glycyrrhizinate (100 μg / ml+10 μg / ml), group IV of lysozyme monoammonium glycyrrhizinate (100 μg / ml+50 μg / ml).

[0107] The method for observing cytopathic changes is the same as in Example 2, and the test results are shown in Table 2. In addition, non-pathological cells were colle...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of lysozyme or a combination comprising the lysozyme to preparation of a medicine for preventing or treating COVID-19 and application to preparation of food for assisting in preventing or treatment COVID-19. The lysozyme or the combination thereof provided by the invention can effectively inhibit cell damage caused by novel coronavirus virus, inhibit inflammatory factor expression induced by novel coronavirus virus, improve airway obstruction and expiratory volume reduction caused by pulmonary lesions, and improve intestinal barrier dysfunction. The composition has a good effect on high virus load, respiratory distress, intestinal function impairment and the like of patients, and can reduce the infection rate of novel coronavirus virus and reduce the novel coronavirus rate of pneumonia severe case. In addition, because the lysozyme is extremely high in safety, the lysozyme also has a very important value for preventing novel coronavirus disease of undiagnosed novel coronavirus virus high-risk infected people.

Description

technical field [0001] The present invention relates to the field of medicine, in particular to a medicine, food and application thereof that can prevent or treat COVID-19 novel coronavirus pneumonia. Background technique [0002] COVID-19 is a new virus belonging to the Coronaviridae family. COVID-19 has certain similarities with SARS coronavirus, but there are also significant differences. In particular, there are obvious differences in viral gene sequence, asymptomatic carriers, infectivity, clinical symptoms, histopathology, etc. Pathological observations show that the degree of pulmonary fibrosis in patients with new coronary pneumonia is lower than that of SARS atypical pneumonia, but the degree of pulmonary hyperplasia and obstruction is higher than that of SARS atypical pneumonia. [0003] At present, some drugs that can be used to treat new coronary pneumonia have been recommended around the world. However, many of them belong to emergency medicine or sympathet...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/47A61K31/704A61K45/06A61P31/14A61P11/00A61P1/00A23L33/10A23L33/125A23L33/17
CPCA23V2002/00A61K31/704A61K38/47A61K45/06A23L33/10A23L33/125A23L33/17A61P1/00A61P11/00A61P31/14C12Y302/01017A61K2300/00A23V2200/30A23V2200/314A23V2200/32
Inventor 孙明杰孙天宇李苌清
Owner GUANGZHOU CENTURY CLINICAL RES CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap